NASH treatment: State of the art in 2020
NASH treatment: State of the art in 2020
Prof. M. F. Abdelmalek
Manal F. Abdelmalek, MD, MPH is Director of Hepatology and institutional lead for investigator-initiated and industry-sponsored multicenter clinical studies, Mayo Clinic, USA. Until recently, she was tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at...
Read MoreNASH treatment: State of the art in 2020
What can we expect from PPAR agonists in the treatment of NASH?
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston
Discovers new clinical trials and new biomarkers
An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Prevalence of NAFLD (non-alcoholic fatty liver disease) affects approximately 25%…
What are the current definitions ? Prof Abdelmalek, USA
So NAFLD (non-alcoholic fatty liver disease) is a spectrum of…